相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma
Barak Pertzov et al.
JOURNAL OF ASTHMA (2021)
Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety
Jermo Johannes van Toor et al.
JOURNAL OF ASTHMA (2021)
Small airway dysfunction and poor asthma control: a dangerous liaison
Marcello Cottini et al.
Clinical and Molecular Allergy (2021)
Asthma in the Precision Medicine Era: Biologics and Probiotics
Chiao-Juno Chiu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Differential Regulation of Interferon Signaling Pathways in CD4+ T Cells of the Low Type-2 Obesity-Associated Asthma Phenotype
Fahd Alhamdan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review
Luigino Calzetta et al.
BIOMEDICINES (2021)
Mepolizumab effectiveness and identification of super-responders in severe asthma
Erin S. Harvey et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma
Michael C Peters et al.
LANCET (2020)
Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype
Corrado Pelaia et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Real-word experience with mepolizumab: Does it deliver what it has promised?
Florence Schleich et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Pharmacotherapeutic strategies for critical asthma syndrome: a look at the state of the art
Alessandro Vatrella et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life
Bruno Sposato et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2020)
Phenotyping severe asthma: a rationale for biologic therapy
Alessandro Vatrella et al.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT (2020)
Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids
Michael C. Peters et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease
Merin E. Kuruvilla et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2019)
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data
Hector Ortega et al.
JOURNAL OF ASTHMA (2019)
Mepolizumab improves small airway function in severe eosinophilic asthma
Claude S. Farah et al.
RESPIRATORY MEDICINE (2019)
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study
Dirkje S. Postma et al.
LANCET RESPIRATORY MEDICINE (2019)
Eosinophil distribution and description in a population cohort of asthmatic patients
Naha Toledo Pons et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
Corrado Pelaia et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study
Corrado Pelaia et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Effects of obesity on asthma: immunometabolic links
Sarah Miethe et al.
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ (2018)
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Corrado Pelaia et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Anti-IL5 therapies for asthma
Hugo A. Farne et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Measuring Eosinophils to Make Treatment Decisions in Asthma
Parameswaran Nair et al.
CHEST (2016)
Association of FEF25-75% Impairment with Bronchial Hyperresponsiveness and Airway Inflammation in Subjects with Asthma-Like Symptoms
Mario Malerba et al.
RESPIRATION (2016)
Inflammation Markers and FEF25-75: A Relevant Link in Children With Asthma
Maria Angela Tosca et al.
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2016)
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
Hector G. Ortega et al.
LANCET RESPIRATORY MEDICINE (2016)
Role of biologics in severe eosinophilic asthma - focus on reslizumab
Girolamo Pelaia et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma
Craig M. Riley et al.
PLOS ONE (2015)
Measurement of FEF25-75% and FEF75% does not contribute to clinical decision making
Philip H. Quanjer et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Characterisation of an OCS-dependent severe asthma population treated with mepolizumab
C. M. Prazma et al.
THORAX (2014)
The role of the small airways in the clinical expression of asthma in adults
Claude S. Farah et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
分享论文
